Relapse in schizophrenia: costs, clinical outcomes and quality of life

被引:213
作者
Almond, S
Knapp, M
Francois, C
Toumi, M
Brugha, T
机构
[1] Univ London London Sch Econ & Polit Sci, London WC2A 2AE, England
[2] Inst Psychiat, London, England
[3] Lundbeck SA, Paris, France
[4] Univ Leicester, Dept Psychiat, Sect Soc & Epidemiol Psychiat, Leicester, Leics, England
关键词
D O I
10.1192/bjp.184.4.346
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background Relapse is one of the most costly aspects of schizophrenia. Aims To compare costs, clinical outcomes and quality of life for patients who experienced relapse in schizophrenia with a control group who did not relapse. Method Patients were randomly selected from current psychiatric case-loads drawn from urban and suburban areas of Leicester. Differences in costs and outcomes by relapse status in the previous 6 months were examined using parametric and non-parametric tests, and multivariate analysis was used to examine factors associated with relapse and costs. Results Costs for the patients who relapsed were over four times higher than those for the non-relapse group. There were few statistically significant differences in clinical and quality of life measures by relapse status. Multivariate analyses suggested some significant correlates of relapse and costs. Conclusions The higher costs associated with relapse will be of interest to policy-makers who face difficult choices concerning new but more expensive treatments for patients with schizophrenia. Declaration of interest None. Funding detailed in Acknowledgements.
引用
收藏
页码:346 / 351
页数:6
相关论文
共 23 条
  • [1] Cost analysis of the treatment of schizophrenia in the UK - A simulation model comparing olanzapine, risperidone and haloperidol
    Almond, S
    O'Donnell, O
    [J]. PHARMACOECONOMICS, 2000, 17 (04) : 383 - 389
  • [2] Beecham J., 2001, Measuring Mental Health Needs, V2nd, P200
  • [3] Beecham J., 1992, MEASURING MENTAL HLT, V2nd
  • [4] PREDICTING RELAPSE IN SCHIZOPHRENIA - THE DEVELOPMENT AND IMPLEMENTATION OF AN EARLY SIGNS MONITORING-SYSTEM USING PATIENTS AND FAMILIES AS OBSERVERS, A PRELIMINARY INVESTIGATION
    BIRCHWOOD, M
    SMITH, J
    MACMILLAN, F
    HOGG, B
    PRASAD, R
    HARVEY, C
    BERING, S
    [J]. PSYCHOLOGICAL MEDICINE, 1989, 19 (03) : 649 - 656
  • [5] The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder
    Bouffard, R
    Hechtman, L
    Minde, K
    Iaboni-Kassab, F
    [J]. CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2003, 48 (08): : 546 - 554
  • [6] ASSESSMENT OF COSTS AND BENEFITS OF DRUG-THERAPY FOR TREATMENT-RESISTANT SCHIZOPHRENIA IN THE UNITED-KINGDOM
    DAVIES, LM
    DRUMMOND, MF
    [J]. BRITISH JOURNAL OF PSYCHIATRY, 1993, 162 : 38 - 42
  • [7] Describing, explaining or predicting mental health care costs: A guide to regression models - Methodological review
    Dunn, G
    Mirandola, M
    Amaddeo, F
    Tansella, M
    [J]. BRITISH JOURNAL OF PSYCHIATRY, 2003, 183 : 398 - 404
  • [8] Guy W, 1976, ECDEU Assessment manual for psychopharmacology, DOI DOI 10.1037/E591322011-001
  • [9] Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia - Results from a randomised clinical trial
    Hamilton, SH
    Revicki, DA
    Edgell, ET
    Genduso, LA
    Genduso, LA
    Tollefson, G
    [J]. PHARMACOECONOMICS, 1999, 15 (05) : 469 - 480
  • [10] A program for relapse prevention in schizophrenia -: A controlled study
    Herz, MI
    Lamberti, JS
    Mintz, J
    Scott, R
    O'Dell, SP
    McCartan, L
    Nix, G
    [J]. ARCHIVES OF GENERAL PSYCHIATRY, 2000, 57 (03) : 277 - 283